Substance in broccoli improves autism symptoms, says study


  • Nutrition
  • Monday, 20 Oct 2014

A dose of a chemical found in broccoli and other vegetables may improve the behavioural and social symptoms of autism in young men, according to a new study.

But for now, people would have to eat a possibly unrealistic amount of broccoli and other vegetables to reach the dose of the molecule – known as sulphoraphane – used in the new study, says the lead researcher.

In the study, those who were given sulphoraphane, found in cruciferous vegetables, were found to have improved in behaviour, social interaction and calmness, says expert. — Filepic

“The extract product we used is not on the market,” says Dr Andrew W. Zimmerman. “There are other things like it but in different forms.”

Sulphoraphane is found in cruciferous vegetables like broccoli, cauliflower and cabbage, but more so in the raw vegetables than cooked. Previous studies have found that it inhibits some bacterial growth and may slow the growth of some cancers.

For the new study, the researchers divided young men with moderate to severe autism spectrum disorder into two groups. One group received varying daily doses of broccoli sprout extract. The others received an inert placebo capsule.

The researchers and caregivers, who did not know which men received extract and which received placebo, regularly rated the young men’s behaviour and social interaction after the trial began. They also rated the participants a month after the trial ended. The men were rated on irritability, tiredness, repetitive movements, hyperactivity, communication, motivation and mannerisms.

The average scores on both scales were better from four weeks onward for the young men assigned to sulphoraphane compared to those in the placebo group, Zimmerman and colleagues reported in the Proceedings of the National Academy of Sciences.

Sulphoraphane may not work for everyone, but for those who do there was a noticeable improvement, says expert. — Filepic

Of the 26 young men given sulphoraphane, 17 were judged to have improved in behaviour, social interaction and calmness by caregivers and staff. There was little change among those in the placebo group.

Sulphoraphane didn’t work for everyone, but for about two-thirds of the group there was a noticeable improvement, Zimmerman says.

“We could tell who was on it and parents could too,” says Zimmerman. “There are several families who just can’t stop praising it.”

Most of the improvements had disappeared by one month after treatment, however.

The researchers write that young people with autism tend to make more eye contact and have improved speech when they have fevers. They suggest that sulphoraphane “stresses” the body like a fever with few or no side effects.

“Stress is not all bad,” Zimmerman says, noting that it can change the way some genes, potentially those governing autism, are expressed.

The participants in the new study were closely monitored and did not suffer from fever.

But most of what is known about the possible effects of fever on autism is based only on anecdotes and any connection is tentative at this point, says Rebecca J. Schmidt, of the department of public health sciences at the University of California Davis School of Medicine.

“Our group has been interested in studying the link between maternal cruciferous vegetable intake and potentially reduced risk of autism in the child,” says Schmidt, who was not involved with the new study.

If individuals with autism eat these vegetables, it should not do a lot of harm and could have benefits, she says.

These results will have to be replicated before they can be confirmed, and it may turn out that this specific broccoli extract isn’t the most effective form for people with autism, Zimmerman says.

Further studies are needed to assess whether the link would be the same for women and younger children, Schmidt says, adding that studies are also needed on whether it may play a role in autism prevention.

Zimmerman was affiliated with The Johns Hopkins University School of Medicinein Baltimore when he collaborated with Dr Paul Talalay, the first person to isolate sulphoraphane, on the design of the trial.

Several clinical trials with sulphoraphane are currently underway, examining its effects on conditions such as asthma, prostate cancer and schizophrenia, according to Clinicaltrials.gov. – Reuters

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
   

Across the site